Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure

BACKGROUND: Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact of cost nor how to integrate cost into medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Birju R., Speight, Candace D., Allen, Larry A., Halpern, Scott D., Ko, Yi‐An, Matlock, Daniel D., Moore, Miranda A., Morris, Alanna A., Scherer, Laura D., Thomson, Mary C., Ubel, Peter, Dickert, Neal W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238635/
https://www.ncbi.nlm.nih.gov/pubmed/35723002
http://dx.doi.org/10.1161/JAHA.121.023789

Ejemplares similares

Ejemplares similares